In a positive development, the Oxford-AstraZeneca Covid-19 vaccine candidate has been approved for emergency use in the United Kingdom.
The approval, by the UK's medicines regulator, means the vaccine is both safe and effective, reports BBC.
The UK has ordered 100 million doses of the vaccine, of which 4m are expected to be available within the next few days.
The Oxford vaccine was tested on the first volunteer in April, and has since been through large-scale clinical trials involving thousands of people.
It is the second Covid-19 vaccine that has received approval from the UK drug regulator. Earlier this month, Pfizer-BioNTech's Covid-19 vaccine candidate has been granted regulatory approval for emergency use in UK.
It should be noted that the Serum Institute of India (SII), the world's largest vaccine maker by volume, has partnered with AstraZeneca for the manufacturing of Oxford-AstraZeneca vaccine.
SII's Covid-19 vaccine candidate, called Covishield, is undergoing the phase-3 trials in India. The company had earlier this month applied for emergency use authorisation from India's drug regulator, which is expected to be granted in the next few days.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.